EP2715582A1 - Appareil et procédé combinant gestion de fonctions cardiaques et thérapies rénales - Google Patents

Appareil et procédé combinant gestion de fonctions cardiaques et thérapies rénales

Info

Publication number
EP2715582A1
EP2715582A1 EP12724503.3A EP12724503A EP2715582A1 EP 2715582 A1 EP2715582 A1 EP 2715582A1 EP 12724503 A EP12724503 A EP 12724503A EP 2715582 A1 EP2715582 A1 EP 2715582A1
Authority
EP
European Patent Office
Prior art keywords
renal
therapy
function management
cardiac function
information
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12724503.3A
Other languages
German (de)
English (en)
Inventor
Deepa Mahajan
Ramesh Wariar
Shibaji Shome
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiac Pacemakers Inc
Original Assignee
Cardiac Pacemakers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers Inc filed Critical Cardiac Pacemakers Inc
Publication of EP2715582A1 publication Critical patent/EP2715582A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362—Heart stimulators
    • A61N1/3621—Heart stimulators for treating or preventing abnormally high heart rate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3623—Means for actively controlling temperature of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3507—Communication with implanted devices, e.g. external control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114—Cardiac control, e.g. by vagal stimulation
    • A61N1/36117—Cardiac control, e.g. by vagal stimulation for treating hypertension

Definitions

  • An implantable or other ambulatory medical device such as a cardiac function management device (CFM) can be used to treat congestive heart failure (CHF or HF) or another heart disorder.
  • CFM devices can include a pacemaker, an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy (CRT) device, a cardiac contractility modulation (CCM) device, a cardiovascular function related neuromodulation device, or a combination device, such as providing a combination of one or more of the above.
  • a renal device can include an external electromechanical system, such as to provide renal therapy, such as renal replacement therapy.
  • a renal device can include a blood pump that can circulate blood through a blood circuit, which can include a hemodialyzer filter.
  • the renal device can be used to provide dialysis, which can include removing small solutes, such as across a semi permeable membrane from a side of higher concentration (e.g., blood side) to a side of lower concentration.
  • the renal device can be used to provide ultrafiltration, which can include removal of water and small- to-medium solutes (e.g., by convection), such as through the application of a hydrostatic pressure across a semi-permeable membrane.
  • the renal device can be used to provide hemofiltration, which can combine ultrafiltration with fluid replacement.
  • the term "clearance" can be used to describe the complete removal of a substance from a specific volume of blood per unit time, in an example, the renal device can combine dialysis, ultrafiltration, hemofiltration, or one or more other renal therapies.
  • Wariar et al. U.S. Patent Publication No. 2007/0175827, entitled CARDIAC FUNCTION MANAGEMENT DEVICE AND SENSOR-SUITE FOR THE OPTIMAL CONTROL OF ULTRAFILTRATION AND REN AL REPLACEMENT THERAPIES, which is incorporated herein by reference, refers to a cardiorenal patient monitoring system with either implanted or non- implanted device(s), remote peripheral device(s), computer network(s), host, and communication means between the device(s), computer network(s), and host useful with an implanted cardiac device and a dialysis machine in renal therapy. (See Wariar et al. at Abstract.)
  • the present inventors have recognized, among other things, that patients with chronic kidney disease (CKD) have more risk of arrhythmias and sudden cardiac death (SCO) than the general population.
  • CKD chronic kidney disease
  • SCO sudden cardiac death
  • the most common cause of death of such CKD patients is cardiac -related.
  • an increasing proportion of HF patients have CKD (e.g., estimated glomerular filtration rate (eGFR) less than 60 mi/min/m 2 ) and 30% of such HF patients experience worsening renal function (e.g., D[Cr] > ().3mg/dl) at a HF hospitalization.
  • eGFR estimated glomerular filtration rate
  • D[Cr] > ().3mg/dl) at a HF hospitalization.
  • About 5% of patients with implanted CFM devices are on dialysis.
  • the present inventors have also recognized that patients on dialysis are at increased risk of cardiac arrhythmias during dialysis, and even following dialysis. This can be due to, for example, increased premature ventricular contractions (PVCs), increased autonomic tone and decreased heart rate variability (HRV), or changes in serum potassium at dialysis, but CFM devices are typically not aware of these periods of increased tachyarrhythmia
  • CFM devices can be made "aware" of dialysis, it can be used to deliver appropriate cardiac support, such as to inhibit or prevent intradialytic hypotension.
  • CFM devices can detect and treat arrhythmias, such as tachyarrhythmias, but typically cannot communicate with renal devices, such as to change dialysis treatment so as to inhibit or prevent tachyarrhythmic events (e.g., by adjusting dialysis potassium).
  • This document describes, among other things, examples of an apparatus or method for integrating operation of cardiac function management and renal replacement therapy devices to improve patient care, such as by using physiological parameters to determine whether a patient is at an increased risk of tachyarrhythmia and adjusting (or recommending adjustment of) the CFM device, the renal device, or both, by communicating appropriately between cardiac and renal therapy devices.
  • FIG. 1 shows an example of portions of a cardiac and renal function management system and an environment in which it is used.
  • FIG. 2 illustrates an example of a method of operating the system, or a portion thereof, such as for using renal information to alter operation of a cardiac function management (CFM) device.
  • CFM cardiac function management
  • FIG. 3 illustrates an example of a method of operating the system, or a portion thereof, such as for using CFM device information to alter operation of a renal device.
  • This document describes, among other things, examples of an apparatus or method for integrating operation of cardiac function management and renal replacement therapy devices to improve patient care, such as by using physiological parameters to determine whether a patient is at an increased risk of tachyarrhythmia and adjusting (or recommending adjustment of) the CFM device, the renal device, or both, by communicating appropriately between cardiac and renal therapy devices.
  • System Overview Example
  • FIG. 1 shows an example of portions of a cardiac and renal function management system 100 and an environment in which it is used.
  • the system 1 ⁇ 0 can include an ambulator ⁇ ' medical device, such as an external (e.g., wearable) medical device or an implantable cardiac rhythm or function management device 102, a local external interface device 104, an optional remote external interface device 1 ⁇ 6, and a renal device 130.
  • an external (e.g., wearable) medical device or an implantable cardiac rhythm or function management device 102 such as an external (e.g., wearable) medical device or an implantable cardiac rhythm or function management device 102, a local external interface device 104, an optional remote external interface device 1 ⁇ 6, and a renal device 130.
  • the implantable device 102 can include an atrial sensing circuit 108, an atrial therapy circuit 110, a ventricular sensing circuit 112, a ventricular therapy circuit 114, a controller circuit 116, a memory circuit 118, a communication circuit 120, a power source such as a batter ⁇ ' 121, a battery status circuit 123, an activity sensor 113 configured to sense a physical activity signal of a patient or other subject, and a physiologic sensor 115 configured to sense a physiologic signal, different from the physical activity signal, of the subject
  • the atrial sensing circuit 108 can be coupled to electrodes, such as an intra-atrial electrode or any other electrode that permits sensing of an intrinsic atrial cardiac signal including atrial depolarization information.
  • the atrial therapy circuit 110 can similarly be coupled to these or other electrodes, such as for delivering pacing, cardiac resynchronization therapy (CRT), cardiac contractility modulation (CCM) therapy, defibrillation/cardioversion shocks, or other energy pulses to one or both atria.
  • CTR cardiac resynchronization therapy
  • CCM cardiac contractility modulation
  • defibrillation/cardioversion shocks or other energy pulses to one or both atria.
  • the ventricular sensing circuit 112 can be coupled to electrodes, such as an intra- ventricular electrode or any other electrode that permits sensing of an intrinsic ventricular cardiac signal including ventricular depolarization information.
  • the ventricular therapy circuit 114 can similarly be coupled to these or other electrodes, such as for delivering pacing, cardiac resynchronization therapy (CRT), cardiac contractility modulation (CCM) therapy, defibrillation/cardioversion shocks, or other energy pulses to one or both ventricles.
  • CTR cardiac resynchronization therapy
  • CCM cardiac contractility modulation
  • defibrillation/cardioversion shocks or other energy pulses to one or both ventricles.
  • the activity sensor 113 can include a single or multiple axis accelerometer, such as to sense an acceleration of the subject that is indicative of physical activity of the subject.
  • the activity sensor 113 can also include a sensor interface circuit, configured to process the acceleration signal and provide a resulting physical activity signal.
  • the physical activity signal can be indicative of a physical exertion of the subject.
  • the activity sensor 113 can also be used for other purposes, such as to sense the subject's posture, heart sounds, or other information available from an acceleration signal.
  • the physiologic sensor 115 can include a respiration sensor, such as an impedance or other sensor, which can include electrodes configured to deliver a test energy, such as to the subject's thorax, and to sense a responsive volta ge signal, such as indicative of the thoracic impedance, and which can be filtered to provide information about respiration, heart contraction, or thoracic fluid accumulation.
  • the physiologic sensor 115 can provide information about heart rate, heart rate variability, autonomic balance, heart vibrations, intracardiac pressure, thoracic fluid status, respiration, patient activity level, temperature, pH, potassium levels, oxygenation, cardiac volumes, blood pressure, or ejection fraction.
  • a controller circuit 116 can be coupled to the atrial sensing circuit 108 and the ventricular sensing circuit 112, such as to receive information from the sensed cardiac signals.
  • the controller circuit 116 can also be coupled to the activity sensor 113 to receive information about the subject's physical activity or exertion level.
  • the controller circuit 116 can also be coupled to the physiologic sensor 115, such as to receive other physiologic information.
  • such other physiologic information can include cardiac contraction signal, such as to provide information about the subject's heart rate or interval, stroke volume, or other information available from the cardiac contraction signal.
  • the other physiologic information can include a respiration signal, such as to provide information about the subject's breathing rate or interval, tidal volume, or other information available from the respiration signal.
  • the controller circuit 116 can include a signal processor circuit, such as a digital signal processor (DSP) circuit, such as for extracting a template parameter from which a diagnostic indicator can be generated, as described below.
  • the signal processor circuit can include dedicated circuitry for performing one or more signal processing functions.
  • the controller circuit 116 can be coupled to the atrial therapy circuit 110 and the ventricular therapy circuit 114 to provide control or triggering signals to trigger timed delivery of the therapy pulses.
  • the controller circuit 116 can be configured to provide control to help permit the CCM therapy to be effectively delivered, such as in combination with one or more other therapies (e.g., bradycardia pacing, antitachyarrhythmia pacing (ATP), cardiac
  • ATP antitachyarrhythmia pacing
  • CTR resynchronizaiion therapy
  • atrial or ventricular defibrillation shock therapy or functionalities (e.g., autothreshold functionality for automatically determining pacing threshold energy, autocapture functionality for automatically adjusting pacing energy to capture the heart, etc.).
  • this can include providing dedicated modules within the controller circuit 116, or providing executable, interpretable, or otherwise performable code configure the controller circuit 116.
  • a memory circuit 118 is coupled to the controller circuit 116, such as to store control parameter values, physiological data, or other information.
  • a communication circuit 120 is coupled to the controller circuit 116 to permit radiofrequency (RF) or other wireless communication with an external device, such as the local external interface device 104 or the remote external interface device 106.
  • RF radiofrequency
  • the battery 121 can include one or more batteries to provide power for the implantable device 102.
  • the battery 121 can be rechargeable, such as by wireless transcutaneous power transmission from an external device to the implantable device 102.
  • the battery status circuit 123 can be communicatively coupled to each of the battery 121 and the controller circuit 116, such as to determine battery status information, for example, indicative of how much energy remains stored in the battery 121.
  • the controller circuit 116 can be configured to al ter operation of the implantable device 102, such as based at least in part on the battery status information.
  • the local external interface device 104 can include a processor circuit 122 and a graphic user interface (GUI) 124 or like device for displaying information or receiving user input as well as a communication circuit, such as to permit wired or wireless communication with the remote external interface device 106 over a communications or computer network.
  • the remote external interlace device 106 can include a processor circuit 126 and a graphic user interface (GUI) 128 or like device for displaying information or receiving user input as well as a communication circuit, such as to permit wired or wireless communication with the local external interface device 104 over the communications or computer network.
  • GUI graphic user interface
  • the system 100 includes processing capability in the ambulatory or implantable device 102 (e.g., provided by the controller circuit 116), the local external interface device 104 (e.g., provided by the processor 122), and the remote external interface device 1 ⁇ 6 (e.g., provided by the processor 126), various methods discussed in this document can be implemented at any of such locations, or tasks can be distributed between two or more of such locations.
  • the system 100 can also include a renal device 130.
  • the renal device 130 can also include a renal device 130.
  • the renal device 13 ⁇ can include a processor circuit 132 and a graphic user interface (GUI) 134 or like device for displaying information or receiving user input.
  • GUI graphic user interface
  • the renal device 13 ⁇ can also include a communication circuit, such as to permit wired or wireless communication with one or more of the remote external interface device 106, the local external interface device 104, or the implantable cardiac function management device 102. Such communication can include communication over a communications or computer network.
  • the renal device 130 can include a renal device, such as for providing renal therapy, such as one or more of hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, intestinal dialysis, or other renal therapy.
  • the renal device 130 can include a wearable, implantable, or other ambulatory renal device 130, or an external non-ambulatory renal device 130, such as an external kidney dialysis machine that can be configured to provide treatment to a dialysis patient at a patient station in a clinical or home setting.
  • the renal device 130 can include a sorbent device, which can include activated charcoal, urease, zirconium phosphate, hydrous zirconium oxide, or activated carbon.
  • the renal device 130 can provide a therapeutic agent, such as potassium, a polypeptide or variant thereof that can prevent, inhibit, delay, or alleviate loss of renal function, or an anticoagulant, such as heparin, prostacyclin, hirudin, or sodium citrate, or other pharmaceutical, biological, or other therapeutic agent.
  • the CFM device 102 or the renal device 130 can be configured to gather and share (e.g., one with the other) physiological information, device operational information, or other information automatically, or by intervention from a user, such as by a caregiver or the patient.
  • the remote external interface device 106 can be configured to store, process, or transmit such information, or other information derived therefrom, such as via a wired or wireless signal, such as via a computer or telecommunications or other network.
  • Information can be communicated between the CFM device 102 and the renal device 130, such as via the local external interface device 104 or the remote external interface device 106, or directly.
  • physiologic information about the subject gathered by the CFM device 102 and shared with the renal device 130 can include information obtained or derived from the physiologic sensor 115, the activity sensor 113, the atrial sensing circuit 108, or the ventricular sensing circuit 112, such as described above.
  • physiologic information gathered by the CFM device 102 to be shared with the renal device 130 can include information about one or more indications of a detected or predicted tachyarrhythmia or a vulnerability to such a tachyarrhythmia.
  • the renal device 13 ⁇ can include one or more
  • physiological sensors 136 from which physiologic information about the subject can be gathered. Such physiologic information, or information derived from such physiologic information obtained by the renal device 130, can be shared with the CFM device 102. Examples of such physiologic sensors 136 that can be included in or coupled to the renal device 130 can include a blood sensor (e.g., such as for sensing blood hematocrit, oxygenation, creatinine, blood urea nitrogen (BUN), albumin, potassium, sodium, calcium, phosphorus, pH , electrolytes, glucose, or one or more other blood constituents), or a dialysate sensor (e.g. such as dialysate BUN, creatinine, electrolytes), or patient monitoring sensors (e.g.
  • a blood sensor e.g., such as for sensing blood hematocrit, oxygenation, creatinine, blood urea nitrogen (BUN), albumin, potassium, sodium, calcium, phosphorus, pH , electrolytes, glucose, or one or more other blood constituents
  • such physiologic information to be shared with the renal device 130 can include information about one or more indications of a detected or predicted tachyarrhythmia or of a vulnerability to such a tachyarrhythmia.
  • device operational information (or information derived from such device operational information) gathered by the CFM device 102 and shared directly or indirectly with the renal device 130 can include information obtained or derived from the batteiy status circuit 123, the controller circuit 116, the memory circuit 118, the atrial therapy circuit 110, the ventricular therapy circuit 114, or the physiologic sensor 115 such as described above.
  • device operational information to be shared by the CFM device 102 with the renal device 130 can include information about one or more indications of a. detected or predicted tachyarrhythmia or of a vulnerability to such a tachyarrhythmia.
  • such device operational information to be shared by the CFM device 102 with the renal device 130 can include information about one or more indications of a device response of the CFM device 102 to a. detected or predicted tachyarrhythmia or of a vulnerability to such a tachyarrhythmia (e.g., scheduling or delivery of antitachyarrhythmia pacing (ATP) or defibrillation shock, or adjusted or enhanced tachyarrhythmia monitoring by the CFM device 102).
  • ATP antitachyarrhythmia pacing
  • the renal device 130 can include one or more operational status monitors or sensors 138, which can include one or more of a flow monitor or sensor (e.g., ultrafiltration rate, clearance , time on dialysis, blood flow, dialysate flow), a pressure sensor (e.g., blood pressure, dialysate pressure), therapeutic agent sensor (e.g., hematocrit, central blood volume), or the like.
  • a flow monitor or sensor e.g., ultrafiltration rate, clearance , time on dialysis, blood flow, dialysate flow
  • a pressure sensor e.g., blood pressure, dialysate pressure
  • therapeutic agent sensor e.g., hematocrit, central blood volume
  • such device operational information obtained by the renal device 130 to be shared with the CFM device 102 cars include information about one or more indications of a detected or predicted tachyarrhythmia or a vulnerability to such a tachyarrhythmia (e.g., such as induced by or monitored during a currently ongoing (e.g., intradialytic) dialysis or other renal therapy episode, or during or between one or more preceding (e.g., interdialytic) dialysis or other renal therapy- episodes.
  • a detected or predicted tachyarrhythmia or a vulnerability to such a tachyarrhythmia e.g., such as induced by or monitored during a currently ongoing (e.g., intradialytic) dialysis or other renal therapy episode, or during or between one or more preceding (e.g., interdialytic) dialysis or other renal therapy- episodes.
  • FIG. 2 illustrates an example of a method 200 of operating the system
  • the CFM device 102 can be operating in a first operating mode.
  • This first operating mode can include a normal operating mode of the CFM device 102.
  • Such normal first operating mode need not account for information about or from the renal device 130; in such mode, the CFM device 102 otherwise provides CFM monitoring or therapy without information about or from the renal device 130.
  • triggering information can be received directly or indirectly by the CFM device 102.
  • Such triggering information can be about or from the renal device 130,
  • Such triggering information can be pertinent to CFM operation, such as by being indicative of a period of increased vulnerability to tachyarrhythmia.
  • the period of increased vulnerability to tachyarrhythmia can include a vulnerable period due to ongoing renal therapy then being delivered by the renal device 130, such as an intradialytic period associated with then-occurring dialysis.
  • the vulnerable period can include an interdialytic period associated with previously- delivered renal therapy, the delivery of which has elapsed, but for which a period of increased tachvaiThythmia vulnerability of the subject remains (e.g., for up to a specified time (e.g., between 3-5 hours (e.g., 4 hours) after cessation of the previous dialysis session) or other condition that serves as an indicator that the patient has stabilized from the previously-delivered renal therapy).
  • a specified time e.g., between 3-5 hours (e.g., 4 hours
  • the CFM device 102 upon receiving the triggering information about or from the renal device 130, can switch from operating in the first operating mode to operating in a different second operating mode.
  • the second operating mode can be configured to be appropriate for use during a period of increased vulnerability to a tachyarrhythmia, such as an intradialytic period or an interdialytic period.
  • the vulnerable period has elapsed (e.g., timed-out or cancelled on the basis of updated triggering information about or from the renal device 130)
  • the CFM device 102 can resume operating in the first operating mode, otherwise process flow can return to 206, and the CFM device 102 can continue operating in the second operating mode.
  • Triggering Information Aboat or From The Renal Device Some illustrative examples of information about or from the renal device 130 that can be used to switch the CFM device 102 from operating in the first operating mode to the second operating mode can include one or more of the following,
  • Ongoing dialysis or other renal therapy has been initiated. This can include triggering a CFM device 102 operating mode switch from the first operating mode to the second operating mode either upon renal therapy initiation or during renal therapy after a specified delay from initiating renal therapy.
  • This renal-related triggering information can be received by the CFM device 102 automatically, such as in response to a. direct or indirect communication generated by the renal device 130, or in response to information about the renal device 130 generated or entered manually into one or more locations of the system 100 by a caregiver, and automatically or manually communicated to the CFM device 102, either directly or indirectly.
  • Initiating dialysis, ultrafiltration, or other renal therapy by the renal device 130 can increase a vulnerability of the subject to tachyarrhythmia during or for a period after the renal therapy.
  • Ongoing dialysis or other renal therapy has been adjusted. This can include triggering a CFM device 102 operating mode switch from the first operating mode to the second operating mode upon or at a specified delay after the renal therapy of the renal device 130 has been changed, such as by adjusting renal therapy flow rate, dialysate composition, therapeutic agent administration or the like. Adjusting dialysis or other renal therapy can alter the vulnerability of the subject to tachyarrhythmia during the renal therapy, or for some period of time that follows cessation of such renal therapy. 3. Dialysis session has been completed.
  • This renal-related triggering information can be received by the CFM device 102 automatically, such as in response to a direct or indirect communication generated by the renal device 130, or in response to information about the renal device 130 generated or entered manually into one or more locations of the system 100 by a caregiver, and automatically or manually communicated to the CFM device 102, either directly or indirectly.
  • Ceasing dialysis or other renal therapy can initiate or prolong a period of vulnerability of the subject to tachyarrhythmia during or for a period after the renal therapy, and the nature of such tachyarrhythmia, vulnerability may be similar to or different from the nature of such tachyarrhythmia vulnerability during the renal therapy.
  • Ongoing or previous renal mon itoring indica tes a physiologic condition. This can include detecting, such as by using the renal device 130, an indication of a physiological condition that can indicate an increased
  • Such detection can occur during renal monitoring by the renal device 130, such as during an ongoing dialysis or other renal therapy session, or during a most recent dialysis or other renal therapy session, or during a more previous dialysis or other renal therapy session, or during a renal monitoring session that did not include providing dialysis or other renal therapy.
  • the CFM device 102 can perform a calibration or self-check function to ensure that such CFM device 102 is performing correctly, such as based on a triggering communication received about or from the renal device 130
  • the physiologic sensor 115 of the CFM device 102 can include a thoracic impedance sensor, such as to compute fluid status for determining pulmonary edema, pleural effusion, hypotension, or to determine minute ventilation (MV), such as for providing an indicator of the metabolic need of the subject for controlling a pacing rate of the subject.
  • MV minute ventilation
  • the fluid stat us or other information measured using thoracic impedance may be affected by fluid being removed or added by the renal device 130, such as during dialysis or ultrafiltration.
  • such information about the renal device 130 can be used to trigger calibration of the thoracic impedance sensor of the CFM device 102.
  • Such information about the renal device 130 can be used to adjust a threshold value to which such raw or signal-processed impedance is compared, such as to declare an abnormal fluid status condition (such as pulmonary edema, or a congestive heart failure decompensation or other CHF status indication that is based at least in part upon detection of such an abnormal fluid stat us condition).
  • an abnormal fluid status condition such as pulmonary edema, or a congestive heart failure decompensation or other CHF status indication that is based at least in part upon detection of such an abnormal fluid stat us condition.
  • the thoracic impedance can be compared to a more stringent (or less stringent) threshold value for declaring a "wet" (hypervolemic) status. This can help inhibit or prevent false positive or false negative volume status indications.
  • physiologic information obtained by the CFM device 102 during or after renal therapy being delivered by the renal device 130 can be qualified or modified in response to triggering information received from the renal device 130.
  • trending of thoracic impedance information used for fluid status determination can flag or disregard data obtained during or immediately following a dialysis or other renal therapy session. This can help reduce or avoid the contribution of known dialysis-induced fluctuations in such data into the patient's fluid status determination. Similar techniques can be applied to other data that can be affected by a dialysis or other renal therapy session. • In an example, a threshold value used by the CFM device 102 to generate an alert condition can be modified in response to triggering information received from the renal device.
  • CFM therapy delivered by the CFM device 102 can be adjusted, such as in the second operating mode, with respect to the first operating mode, such as in response to triggering information about or from the renal device 130 indicating an ongoing or previous renal therapy session carried out by the renal device 130, or in response to physiological or device operating triggering information about or from the renal device 13 ⁇ that can indicate a need to adjust the CFM therapy.
  • dialysis or other renal therapy can cause or increase the potential for hypotension in the subject.
  • the CFM device 102 can adjust CFM therapy being delivered, such as to increase cardiac output to inhibit or prevent hypotension.
  • Illustrative examples of adjusting CFM therapy in the second operating mode can include:
  • nerves for example, pulmonary artery pressure receptors, cardiopulmonary baroreceptors
  • ganglia for example, pulmonary artery pressure receptors, cardiopulmonary baroreceptors
  • electrostimulation electrode configuration such as from single- chamber ventricular pacing to biventricular or dual chamber pacing, so as to increase spatial coordination; ⁇ adjusting an interelectrode delay between same-chamber (e.g., between multiple left-ventricular electrodes on a quadripolar coronary sinus or other multi-electrode lead) or different chamber (e.g., atrioventricular (AV) delay, biventricular (RV-LV delay), etc.) electrostimulations delivered during the same cardiac cycle;
  • AV atrioventricular
  • RV-LV delay biventricular
  • ⁇ initiate or adjust a His-bundle pacing, such as for providing bi-ventricular coordination of ventricular heart contractions from a right ventricular (RV) septal location at or near the His-bundle, at which an electrostimulation delivered; or
  • ⁇ adjusting anti-iachyarrhythmia therapy such as by changing the number of high-rate or morphologically-abnormal beats needed to declare detection of a tachyarrhythmia episode to discriminate between different types of tachyarrhythmia beats, or by changing a response to a detected
  • tachyarrhythmia such as to increase or decrease the likelihood of delivering ATP vs. a shock, or the shock energy.
  • the CFM device 102 can respond to the triggering information provided by the renal device 130 by storing the triggering information or other physiologic or device operating information provided by the renal device 130, such as in conjunction with information from the CFM device 102, either at the CFM device 102, at the remote external interface device 106, at the local external interface device 104, or at the renal device 130. This can allow information from both the CFM device 102 and the renal device 130 to be used together, such as to adjust or coordinate current or future operation of one or both of the CFM device 102 or the renal device 130.
  • physiologic or device operational parameters provided by the renal device 130 during a dialysis or other renal therapy session, or within a specified time following such a. renal therapy session can include one or more parameters that can be indicative of a tachyarrhythmia vulnerability (e.g., electrolyte imbalance, renal therapy flow rate or composition), which can be stored in conjunction with the CFM physiologic or device operational parameters, such as for altering (either automatically, or by suggesting such modification to a physician or other caregiver) current or future CFM therapy.
  • a tachyarrhythmia vulnerability e.g., electrolyte imbalance, renal therapy flow rate or composition
  • such information can yield information about a threshold for inducing tachyarrhythmia vulnerability via the renal therapy, and the CFM therapy can be configured to avoid such threshold of tachyarrhythmia vulnerability, such as during or after such a. renal therapy session.
  • FIG. 3 illustrates an example of a method 300 of operating the system 100, or a portion thereof.
  • the renal device 130 can be operating in a first operating mode.
  • This first operating mode can include a normal operating mode of the renal device 130.
  • Such normal first operating mode need not account for information about or from the CFM device 102; in such mode, the renal device 130 otherwise provides renal monitoring or therapy without information about or from the CFM device 102.
  • triggering information can be received directly or indirectly by the renal device 130.
  • Such triggering information can be about or from the CFM device 102.
  • Such triggering information can be pertinent to renal device 130 operation, such as by being indicative of a period of increased vulnerability to tachyarrhythmia.
  • the period of increased vulnerability to tachyarrhythmia can include a vulnerable period detected or determined by the CFM device 102, such as a previous or current indication of a detected or predicted tachyarrhythmia.
  • the renal device 130 can switch from operating in the first operating mode to operating in a different second operating mode.
  • the second operating mode can be configured to be appropriate for use during a period of increased vulnerability to a tachyarrhythmia, such as indicated by the CFM device 102.
  • the vulnerable period has elapsed (e.g., timed- out or cancelled on the basis of updated triggering information about or from the CFM device 102)
  • the renal device 130 can resume operating in the first operating mode, otherwise process flow can return to 3 ⁇ 6, and the renal device 130 can continue operating in the second operating mode.
  • Examples of Triggering Information About or From The CFM. Device Some illustrative examples of information about or from the CFM device 1 ⁇ 2 that can be used to switch the renal device 130 from operating in the first operating mode to the second operating mode can include one or more of the following.
  • the CFM device 102 can be configured to detect heart contractions, such as from an intrinsic cardiac signal obtained from the atrial sensing circuit 108 or the ventricular sensing circuit 112, or from the physiologic sensor 115 (e.g., an impedance- based cardiac contraction signal, or a mechanical or fluid-based cardiac contraction signal). From such detected heart contractions, an intrinsic heart rate can be determined, such as by the controller circuit 116.
  • a heart rate variability (HRV) indication can also be determined, such as from time intervals between the detected heart contractions, by the controller circuit 116,
  • HRV heart rate variability
  • the HRV can be trended over time.
  • a decrease in HR V can indicate sympathetic over- assertion in the sympafhovagal balance of the autonomic nerv ous system of the subject. Such decreased HRV, therefore, can indicate an increased vulnerability to tachyarrhythmia.
  • PVC/PACs can indicate an increased vulnerability to tachyarrhythmia, particularly when combined with other physiologic information, such as the physical activity of the subject.
  • post-exercise PVC/PACs can be particularly indicative of a tachyarrhythmia vulnerability.
  • the occurrence, count, or frequency of long-short sequences of temporally adjacent intervals between temporally adjacent heart contractions can also be indicative of a tachyarrhythmia vulnerability.
  • the occurrence, count, or frequency of prolonged rate-adjusted QT intervals can also be indicative of a tachyarrhythmia vulnerability.
  • the occurrence, count, or frequency of short can indicate an increased vulnerability to tachyarrhythmia, particularly when combined with other physiologic information, such as the physical activity of the subject.
  • post-exercise PVC/PACs can be particularly indicative of a tachyarrhythmia vulnerability.
  • RR intervals between ventricular contractions e.g., high intrinsic contraction rate, such as in the absence of accompanying physical activity
  • abnormal-morphology beats can also be indicative of a tachyarrhythmia vulnerability or an ongoing tachyarrhythmia.
  • Information about HRV, about a decrease in HRV corresponding to an increased risk of tachyarrhythmia, about the occurrence or prevalence of PVC/PACs indicative of tachyarrhythmia vulnerability, about the occurrence or prevalence of long-short sequences of adjacent heart contraction intervals, about the occurrence or prevalence of rate-adjusted prolonged QT intervals, or about high rate of heart contractions or abnormal-morphology beats, can be communicated from the CFM device 102 to the renal device 130, such as to provide triggering information to permit the renal device 130 to adjust its operation accordingly during or after such tachyarrhythmia vulnerable period, such as to reduce the risk of renal therapy being delivered by the renal device 130 from inducing or exacerbating a tachyarrhythmia in the subject.
  • the CFM device 102 can include one or more physiologic sensors 115 that can include one or more of a thoracic fluid sensor, heart sound sensor, or pulmonary artery pressure (PAP) sensor, which can provide information that can be used for determining fluid status. Such sensors can be used to determine the fluid state of the patient during and following dialysis therapy. Such information can be provided by the CFM device 102 to the renal device 130, such as to provide triggering information to initiate, adjust, or titrate dialysis, ultrafiltration, or other renal therapy delivered by the renal device 130.
  • a thoracic fluid sensor can include one or more of a thoracic fluid sensor, heart sound sensor, or pulmonary artery pressure (PAP) sensor, which can provide information that can be used for determining fluid status.
  • PAP pulmonary artery pressure
  • Such information can be provided by the CFM device 102 to the renal device 130, such as to provide triggering information to initiate, adjust, or titrate dialysis, ultrafiltration, or other renal therapy delivered by the renal device
  • thoracic impedance corresponds to decreased thoracic fluid accumulation and therefore thoracic impedance determined by the CFM device 102 can be used to indicate a vulnerability of the subject to arrhythmias or hypotension in response to thoracic fluid status.
  • Information about the subject's fluid status or increased vulnerability to tachyarrhythmia can be communicated from the CFM device 102 to the renal device 130, such as to provide triggering information to initiate, adjust, or titrate dialysis, ultrafiltration, or other renal therapy.
  • the CFM device 102 can include a physiologic sensor 115 that can include a chemical sensor, such as for detecting the amount of potassium, calcium, or another substance in the subject's bloodstream. Information from such chemical sensor included in or coupled to the CFM device 102 can be provided by the CFM device 102 to the renal device
  • chemical information determined by the CFM device 102 can be used to indicate a heightened vulnerability of the subject to tachyarrhythmia, such as can exist when there are significant changes in serum potassium and other electrolytes during or immediately following dialysis indicative of an increased vulnerability to tachyarrhythmia.
  • Information about the potassium level or other chemical information indicating increased vulnerability to tachyarrhythmia can be communicated from the CFM device 102 to the renal device 130, such as to provide triggering information to initiate, adjust, or titrate dialysis, ultrafiltration, or other renal therapy,
  • the CFM device 102 can indirectly detect renal status or renal therapy status information, such as the onset or termination of renal therapy, such as ultrafiltration.
  • renal status or renal therapy status information such as the onset or termination of renal therapy, such as ultrafiltration.
  • ultrafiltration -related hemoconcentration can be detected using a blood conductivity characteristic sensor, such as a blood impedance sensor.
  • the blood impedance sensor can include two electrodes that can be located on a distal portion of an intravascular lead that can be included in or coupled to the CFM device 102.
  • More than two electrodes can be used to perform such impedance sensing, such as to implement a three-point or a four- point probe for performing such blood impedance sensing or other blood conductivity characteristic sensing (e.g., voltage sensing, transconductance sensing, transimpedance sensing, or other blood conductivity characteristic sensing).
  • the electrodes can be, but need not both be, located within the same blood vessel or heart chamber.
  • One or more other components of the sensed conductivity characteristic signal can be filtered or otherwise signal processed, such as to remove a respiration component of an impedance signal, a cardiac stroke component of the impedance signal, or the like.
  • an increase in blood impedance can indicate an increased hemoconcentration (which, in turn, can indicate onset of ultrafiltration) and a decrease in blood impedance can indicate a decreased hemoconcentration (which , in turn, can indicate termination of ul trafiltration).
  • Such indirect sensing of a renal therapy parameter cars also use one or more other physiological or other signals.
  • information about the sensed blood conductivity characteristic can be combined with information about the time of day, information about the subject's posture (e.g., sensed using a 3- axis acceierometer or other posture sensor that can be included in the CFM device 102).
  • the sensed blood conductivity characteristic information can be combined with one or more of the time of day or the posture information to compensate for one or both such effects on the blood conductivity characteristic or the hemoeonduetivity, such that a better correlation between sensed blood conductivity information and hemoconcentation or other indirect renal information can be determined with better sensitivity, specificity, or both. Examples of CFM-Res posisive Second Operating Mode of the Renal Device
  • the renal device 130 can respond to the triggering information provided by the CFM device 102 by initiating, adjusting, or titrating dialysis or ultrafiltration.
  • a fluid- accumulation indication provided by the CFM device 102 can be responded to by initiating or increasing dialysis or ultrafiltration by the renal device 130.
  • the renal device 13 ⁇ responsive to triggering information from the CFM device 102 indicating a tachyarrhythmia vulnerability (e.g., decreased HRV, thoracic fluid accumulation, electrolyte imbalance or other blood chemical information, reduced blood flow, or the like), the renal device 13 ⁇ can respond by initiating, adjusting, or titrating dialysis, ultrafiltration, or composition of the dialysate,
  • the renal device 130 can respond to the triggering information provided by the CFM device 102 by initiating, adjusting, or titrating infusion, such as responsive to such triggering information indicating a tachyarrhythmia episode or intradialytic hypotension (e.g., from PAP, heart sound, thoracic impedance-derived fluid accumulation, or other indication of
  • a fluid-accumulation indication provided by the CFM device 102 can be responded to by initiating or increasing infusion of a therapeutic agent such as a plasma expander by the renal device 130.
  • a therapeutic agent such as a plasma expander
  • the renal device 130 responsive to triggering information from the CFM device 102 indicating a tachyarrhythmia vulnerability (e.g., decreased HRV, impedance-indicated fluid accumulation, electrolyte imbalance or other blood chemical information, reduced blood flow, or the like), the renal device 130 can respond by initiating, adjusting, or titrating infusion, such as by ceasing or reducing infusion of the therapeutic agent or th at of an electrolyte causing an electrolytic imbalance, or by initiating or increasing infusion of an anti- tachyarrhythmic drug, a balancing electrolyte, or other therapeutic agent.
  • the renal device 130 can respond to the triggering information provided by the CFM device 102 by initiating, adjusting, or titrating dialysis, such as responsive to such triggering (e.g., from PAP, heart sound, thoracic impedance-derived fluid accumulation).
  • a fluid- accumulation indication provided by the CFM device 102 can be responded to by initiating or modifying the therapy offered by renal device 130, such as within a dialysate during dialysis.
  • the renal device 130 can respond, such as by:
  • initiating, adjusting, or titrating dialysis such as by ceasing or reducing dialysate infusion of a diuretic agent or that of an electrolyte causing an electrolytic imbalance
  • ⁇ adjusting a parameter of a subsequent dialysis or other renal therapy session.
  • the renal device 130 can respond to the triggering information provided by the CFM device 102 by storing the triggering information or other physiologic or device operating information provided by the CFM device 102, such as in conj unction with information from the renal device 130, either at the renal device 130, at the remote external interface device 1 ⁇ 6, at the local external interface device 104, or at the CFM device 102, This can allow information from both the CFM device 102 and the renal device 130 to be used together, such as to adjust or coordinate current or future operation of one or both of the CFM device 102 or the renal device 130.
  • physiologic parameters sensed by the CFM device 102 during a dialysis or other renal therapy session, or within a specified time following such a renal therapy session can include one or more parameters that can be indicative of a tachyarrhythmia vulnerability (e.g., heart rate, HRV, prolonged QT interval, PVCs, long-short contraction sequences, heart sound indicating changes in volume status or contractility, pressure indicating changes in volume status, thoracic impedance indicating changes in thoracic or body fluid status, blood anaiyte indicating electrolyte imbalance or poor blood oxygenation), which can be stored in conjunction with the particular dialysis or other renal therapy parameters, such as for altering (either automatically, or by suggesting such modification to a physician or other caregiver) a subsequent renal therapy session.
  • a tachyarrhythmia vulnerability e.g., heart rate, HRV, prolonged QT interval, PVCs, long-short contraction sequences, heart sound indicating changes in volume status or contractility, pressure indicating
  • the renal device 130 and the CFM device 102 can jointly provide physiological or other information, such as can be used as triggering information at 204 or 304.
  • the triggering information received from the renal device 130 at 204 can include information generated by the renal device 130 in conjunction or cooperation with the CFM device 102
  • the triggering information received from the CFM device 102 at 304 can include information generated by the CFM device 102 in conjunction or cooperation with the renal device 130.
  • An illustrative example of cooperation between the CFM device 102 and the renal device 130 can include or use an extracorporeal blood circuit, through which the renal device 130 is coupled to a patient's circulatory system, such as for performing hemodialysis, hemofiltration, hemodiafiltration, ultrafiltration, or the like.
  • the renal device 130 can modify a parameter (e.g., blood temperature, or blood conductivity), which can be detected using a CFM device 102 (e.g., using a. thermodiiution technique to detect a change in blood temperature at a temperature sensor that can be located on a distal or other portion of an intravascular lead that can be included in or coupled to the CFM device 102),
  • a thermodiiution technique to detect a change in blood temperature at a temperature sensor that can be located on a distal or other portion of an intravascular lead that can be included in or coupled to the CFM device 102
  • the renal device 130 can include a blood or dialysate heater or cooler that can heat or cool a bolus of blood or dialysate passing through the extracorporeal blood circuit.
  • the CFM device 102 can include a temperature sensor, such as can be located on a distal or other portion of an intravascular lead that can be included in or coupled to the CFM device 102.
  • a transit time between (1) the location in the extracorporeal blood circuit at which the blood temperature was modified by the renal device 130 and (2) the location at which blood temperature or change in blood temperature is detected using the CFM device 102 can be measured, such as for use in calculating one or more physiological parameters, such as blood flow velocity, cardiac output, central blood volume, or any combination thereof, or for calculating another physiological or other parameter of interest.
  • the renal device 130 can include a blood conductivity modulator, such as a dialysate or other mfusate pump or other dispensing device.
  • the blood conductivity can be modulated by adjusting one or more of the volume of dialysate or other mfusate introduced by the blood conductivity modulator, or the content of the solution being infused.
  • hypertonic saline can be introduced, by itself, or mixed with another dialysate or other infusate, to adjust the conductivity of a bolus of blood passing through the extracorporeal blood circuit to which the renal device 130 is coupled.
  • the CFM device 102 can include an impedance or other blood conductivity characteristic detector (e.g., such as described herein, using electrodes located on a distal or other portion of an intravascular lead) that can detect the arrival of a conductivity -modulated bolus of blood.
  • a transit time between (1) the location in the extracorporeal blood circuit at which the blood conductivity was modified by the conductivity modulator device component of the renal device 130 and (2) the location at which blood conductivity or change in blood conductivity is detected using the CFM device 102 can be measured, such as for use in calculating one or more physiological parameters, such as blood flow velocity, cardiac output, central blood volume, or any combination thereof, or for calculating another physiological or other parameter of interest.
  • Example 1 can include subject matter (such as an system, apparatus, method, tangible machine readable medium, etc.) that can include a wearable or implantable ambulatory cardiac function management (CFM ) device.
  • the CFM device can include a data input configured to receive information about or from an external renal monitoring or therapy device.
  • the subject matter can include first and second operating modes, such as of a control circuit.
  • the first operating mode can control operation of the implantable cardiac function management device in the absence of triggering information about or from the renal monitoring or therapy device.
  • the second operating mode can control operation of the implantable cardiac function management device in response to recei ving triggering information about or from the renal monitoring or therapy device.
  • the second operating mode can include an exit condition, which can return control of operation of the implantable cardiac function management de vice to the first operating mode, when a vulnerable period has elapsed.
  • the vulnerable period can include a time period corresponding to an increased risk of tachyarrhythmia or intradialytic hypotension.
  • the subject matter of Example 1 can include the control circuit being configured to adjust or direct therapy, provided by the cardiac function management device, in response to the triggering information received from the renal monitoring or therapy device.
  • Example 3 the subject matter of any one of Examples 1-2 can include the control circuit being configured to adjust or direct an anti-tadiyarrhytlimia therapy, provided by the cardiac function management device, in response to the triggering information received from the renal monitoring or therapy device.
  • Example 4 the subject matter of any one of Examples 1 -3 can include the control circuit being configured to adjust or direct a physiological sensor of the cardiac function management device in response to the triggering information received from the renal monitoring or therapy device.
  • Example 5 the subject matter of any one of Examples 1-4 can include the control circuit being configured to qualify or flag data, from the physiological sensor of the cardiac function management device using the triggering information received from the renal monitoring or therapy device.
  • Example 6 the subject matter of any one of Examples 1 -5 can include the control circuit being configured to adjust determination of a thoracic fluid accumulation status or a congestive heart failure (CHF) status in response to the triggering information received from the renal monitoring or therapy device.
  • CHF congestive heart failure
  • Example 7 the subject matter of any one of Examples 1-6 can include the operating mode of the cardiac function management device being adjusted in response to the triggering information received from the renal monitoring or therapy device, wherein the triggering information indicates at least one of: (1) initiation of renal therapy; (2) adjustment of ongoing renal therapy; (3) cessation of renal therapy; or (4) a physiologic condition indicated by the renal monitoring or therapy device.
  • Example 8 the subject matter of any one of Examples 1-7 can include the second operating mode of the cardiac function management device adjusting, with respec t to the first operating mode, at least one of pacing rate,
  • Example 9 the subject matter of any one of Examples 1 -8 can include logging (e.g., at the CFM device) information received by the CFM device about or from an external renal monitoring or therapy device.
  • Example 10 can include, or can be combined with any one of Examples 1-9 to include, subject matter (such as an system, apparatus, method, tangible machine readable medium, etc) such as can include or use an apparatus comprising a renal monitoring or therapy device.
  • the renal monitoring or therapy device can include a tachyarrhythmia vulnerability detection circuit, which can be configured to monitor a patient physiological or device operational renal parameter that varies during or in response to renal therapy.
  • the renal monitoring or therapy device can be configured to determine whether the renal parameter indicates a vulnerable period corresponding to an increased risk of a present or future tachyarrhythmia episode.
  • the renal monitoring or therapy device can include a. communication circuit, configured to communicate directly or indirectly to an ambulatory cardiac function management device to provide a tachyarrhythmia vulnerability mode trigger configured to alter operation of the cardiac function management device in response to the trigger.
  • Example 1 the subject matter of any one of Examples 1-10 can comprise the renal monitoring or therapy device including a control circuit that is configured to direct therapy provided by the renal monitoring or therapy device in response to information received from the cardiac function
  • management device about at least one of a. tachyarrhythmia, vulnerability of the subject, a fluid accumulation status of the subject, or a heart failure status of the subject.
  • Example 12 the subject matter of any one of Examples 1-11 can include the renal monitoring or therapy device being configured to adjust or direct an anti -tachyarrhythmia therapy, provided by the cardiac function management device.
  • Example 13 the subject matter of any one of Examples 1 -12 can include the renal monitoring or therapy device being configured to adjust determination of a thoracic fluid accumulation status or a congestive heart failure (CHF) status by the cardiac function management device.
  • the subject matter of any one of Examples 1 -13 can include the renal monitoring or therapy device being configured to adjust an operating mode of the cardiac function management device using information about at least one of: (1) initiation of renal therapy; (2) adjustment of ongoing renal therapy; (3) cessation of renal therapy; or (4) a physiologic condition indicated by the renal monitoring or therapy device.
  • CHF congestive heart failure
  • Example 15 the subject matter of any one of Examples 1- 14 can include the control circuit of the renal monitoring or therapy de vice being configured to adjust or direct the renal monitoring therapy, in response to the information received from the cardiac function management device, by providing a control signal to modify at least one of the following: dialysis, blood flow rate, dialysate flow rate, ultrafiltration, dialysate composition, or infusion.
  • Example 16 the subject matter of any one of Examples 1- 15 can include logging (e.g., at the renal monitoring or therapy device) information received from or about the cardiac function management device.
  • Example 17 the subject matter of any one of Examples 1 -16 can include altering operation of the renal monitoring or therapy device in response to information received from or about the cardiac function management device.
  • Example 18 can include, or can be combined with any one of Examples
  • subject matter such as an system, apparatus, method, tangible machine readable medium, etc.
  • an implantable or wearable ambulator ⁇ ' cardiac function management device comprising a tachyarrhythmia detection or prediction circuit, which can be configured to detect the presence of an existing or a predicted future tachyarrhythmia episode.
  • the cardiac function management device can include a communication circuit, configured to communicate directly or indirectly to an external renal monitoring or therapy device triggering information that is configured to alter operation of the renal monitoring or therapy in response to the triggering information.
  • Example 19 the subject matter of any one of Examples 1 -18 can include the communication circuit being configured to communicate directly or indirectly to an external renal monitoring or therapy device triggering information indicating a tachyarrhythmia vulnerability including at least one of: heart rate, heart rate variability, premature ventricular contraction information, long-short, corstractiors sequence information, prolonged QT interval information, or blood analyte information.
  • triggering information indicating a tachyarrhythmia vulnerability including at least one of: heart rate, heart rate variability, premature ventricular contraction information, long-short, corstractiors sequence information, prolonged QT interval information, or blood analyte information.
  • Example 20 the subject matter of any one of Examples 1-19 can include the communication circuit being configured to communicate directly or indirectly, to an external renal monitoring or therapy device, triggering information that is configured to adjust or direct the renal or monitoring therapy, including at least one of the following: ultrafiltration, infusion, or dialysis.
  • Example 21 the subject matter of any one of Examples 1 -20 can include logging (e.g., at the cardiac function management device) information received from our about the renal monitoring or therapy device.
  • Example 22 can include, or can be combined with any one of Examples 1-21 to include, subject matter that can include (such as an system, apparatus, method, tangible machine readable medium, etc.) detecting a tachyarrhythmia vulnerable period using at least one of an ambulatory cardiac function management device or an renal therapy device.
  • triggering information can be communicated to the other of the cardiac function management device or the renal therapy device to trigger such other of the cardiac function management device or the renal therapy device to switch from a first operating mode to a second operating mode, wherein the second operating mode is configured for use during the tachyarrhythmia vulnerable period.
  • Example 23 the subject matter of any one of Examples 1-22 can include switching the cardiac function management device from the first operating mode to the second operating mode.
  • the second operating mode of the cardiac function management device can include adjusting, with respect to the first operating mode, at least one of pacing rate, electrostimulation energy , electrostimulation electrode configuration, interelectrode electrostimulation delay, His-bundle pacing, or anti-taehyarrhythmia therapy.
  • Example 24 the subject matter of any one of Examples 1 -23 can include the renal monitoring or therapy device being configured to adjust an operating mode of the cardiac function management device using information about at least one of: (1) initiation of renal therapy; (2) adjustment of ongoing renal therapy; (3) cessation of renal therapy; or (4) a physiologic condition indicated by the renal monitoring or therapy device.
  • Example 25 the subject matter of any one of Examples 1 -24 can include logging (e.g., at the renal device) information received from or about the cardiac function management device.
  • Example 26 the subject matter of any one of Examples 1-25 can include adjusting renal therapy in response to information received from or about the cardiac function management device.
  • present inventors also contemplate examples in which only those elements shown or described are provided. Moreover, the present inventors also contemplate examples using any combination or permutation of those elements shown or described (or one or more aspects thereof), either with respect to a particular example (or one or more aspects thereof), or with respect to other examples (or one or more aspects thereof ) shown or described herein.
  • Method examples described herein can be machine or computer- implemented at least in part. Some examples can include a. computer-readable medium or machine-readable medium encoded with instructions operable to configure an electronic device to perform methods as described in the above examples.
  • An implementation of such methods can include code, such as microcode, assembly language code, a higher-level language code, or the like. Such code can include computer readable instructions for performing various methods. The code may form portions of computer program products. Further, in an example, the code can be tangibly stored on one or more volatile, non- transitory, or non-volatile tangible computer-readable media, such as during execution or at other times.
  • Examples of these tangible computer-readable media can include, but are not limited to, hard disks, removable magnetic disks, removable optical disks (e.g., compact disks and digital video disks), magnetic cassettes, memory cards or sticks, random access memories (RAMs), read only memories (ROMs), and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • External Artificial Organs (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

La présente invention concerne un système pouvant coordonner les opérations d'un dispositif de gestion de fonctions cardiaques (CFM) et d'un dispositif rénal, par exemple pendant une période de vulnérabilité durant laquelle un patient présente un risque accru de tachyarythmie.
EP12724503.3A 2011-05-23 2012-05-22 Appareil et procédé combinant gestion de fonctions cardiaques et thérapies rénales Withdrawn EP2715582A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161488898P 2011-05-23 2011-05-23
PCT/US2012/038920 WO2012162281A1 (fr) 2011-05-23 2012-05-22 Appareil et procédé combinant gestion de fonctions cardiaques et thérapies rénales

Publications (1)

Publication Number Publication Date
EP2715582A1 true EP2715582A1 (fr) 2014-04-09

Family

ID=46178845

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12724503.3A Withdrawn EP2715582A1 (fr) 2011-05-23 2012-05-22 Appareil et procédé combinant gestion de fonctions cardiaques et thérapies rénales

Country Status (3)

Country Link
EP (1) EP2715582A1 (fr)
JP (1) JP5778860B2 (fr)
WO (1) WO2012162281A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10667736B2 (en) 2014-12-17 2020-06-02 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for assessing sympathetic nervous system tone for neuromodulation therapy
US10335534B2 (en) * 2015-11-06 2019-07-02 Medtronic, Inc. Dialysis prescription optimization for decreased arrhythmias

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0422271B1 (fr) * 1989-10-11 1998-02-04 Pacesetter AB Appareil médical implantable dans le corps d'un être vivant comportant des moyens de stimulation de contraction de tissus
US7529580B2 (en) 2005-08-11 2009-05-05 Pacesetter, Inc. Detection of renal failure by cardiac implantable medical device
US8246563B2 (en) * 2006-02-02 2012-08-21 Cardiac Pacemakers, Inc. Cardiac rhythm management device and sensor-suite for the optimal control of ultrafiltration and renal replacement therapies
US7664548B2 (en) * 2006-10-06 2010-02-16 Cardiac Pacemakers, Inc. Distributed neuromodulation system for treatment of cardiovascular disease
US8121688B2 (en) * 2009-06-12 2012-02-21 Pacestter, Inc. Method and system for automatically switching between modes of an implantable medical device
WO2011049716A1 (fr) * 2009-10-19 2011-04-28 Cardiac Pacemakers, Inc. Système de stimulation électrique cardiorénal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012162281A1 *

Also Published As

Publication number Publication date
JP2014515965A (ja) 2014-07-07
JP5778860B2 (ja) 2015-09-16
WO2012162281A1 (fr) 2012-11-29

Similar Documents

Publication Publication Date Title
US20120303079A1 (en) Apparatus and method for combined cardiac function management and renal therapies
US9592327B2 (en) Systems and methods for heart failure management
US7505814B2 (en) System and method for evaluating heart failure based on ventricular end-diastolic volume using an implantable medical device
US10750996B2 (en) Multi-sensor body fluid volume index
US9456755B2 (en) Method and device to monitor patients with kidney disease
US7272443B2 (en) System and method for predicting a heart condition based on impedance values using an implantable medical device
EP2701580B1 (fr) Dispositif pour suivre des patients atteints d'une maladie rénale
EP2163195B1 (fr) Système pour surveiller les niveaux de fluides thoraciques basé sur l'impédance utilisant un dispositif médical implantable
JP4774054B2 (ja) ヘマトクリットを推定するためのデバイス
US7437192B2 (en) System and method for detecting heart failure and pulmonary edema based on ventricular end-diastolic pressure using an implantable medical device
US7899522B1 (en) System and method for discriminating acute and chronic heart failure using an implantable medical device
US20120190991A1 (en) System and Method for Detecting a Clinically-Significant Pulmonary Fluid Accumulation Using an Implantable Medical Device
EP2143467B1 (fr) Systèmes pour une utilisation par un dispositif médical implantable pour détecter une insuffisance cardiaque d'après le contenu informationnel indépendant de vecteurs d'immittance
US20120184859A1 (en) Systems and methods for corroborating impedance-based left atrial pressure (lap) estimates for use by an implantable medical device
US10194820B2 (en) Method and apparatus for detecting atrial tachyarrhythmia using heart sounds
US8282562B2 (en) System and method for monitoring cardiopulmonary fluid transfer rates using an implantable medical device
US20100234906A1 (en) System and method for controlling rate-adaptive pacing based on a cardiac force-frequency relation detected by an implantable medical device
US8135468B2 (en) Systems and methods for estimating left atrial pressure (LAP) in patients with acute mitral valve regurgitation for use by an implantable medical device
WO2009012094A1 (fr) Dispositif de surveillance cardiaque osmométrique et ses procédés
US20110251496A1 (en) Volume depletion detection
EP2715582A1 (fr) Appareil et procédé combinant gestion de fonctions cardiaques et thérapies rénales
US20130116583A1 (en) Systems and methods for predicting and corroborating pulmonary fluid overloads using an implantable medical device
US8750981B2 (en) Systems and methods for assessing heart failure and controlling cardiac resynchronization therapy using hybrid impedance measurement configurations
US7596411B1 (en) Apparatus and method for two-component bioelectrical impedance ratio measuring and monitoring
EP4212206A1 (fr) Système de stimulateur cardiaque

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160323